- Home
- ACIC vs VALN Comparison
ACIC vs VALN Comparison
Compare ACIC & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | VALN |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.7M | 582.2M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACIC | VALN |
|---|---|---|
| Price | $10.39 | $5.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $12.28 |
| AVG Volume (30 Days) | ★ 245.9K | 17.7K |
| Earning Date | 10-29-2026 | 11-24-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | ★ 39.61 | N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $87.84 |
| P/E Ratio | $8.29 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.01 | $4.75 |
| 52 Week High | $13.06 | $12.18 |
Technical Indicators
Market Signals| Indicator | ACIC | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 50.15 |
| Support Level | $9.79 | $5.16 |
| Resistance Level | $11.48 | $6.60 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | -0.12 | 0.06 |
| Stochastic Oscillator | 36.43 | 57.61 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.